Bicyclic Pyrrolidine Inhibitors of Toxoplasma gondii Phenylalanine t-RNA Synthetase with Antiparasitic Potency In Vitro and Brain Exposure
ACS Infectious Diseases · 2024
DOI: 10.1021/acsinfecdis.4c00170 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, 2024. Verfasst von Chloe C Ence und 11 weiteren Autor:innen. Beteiligte Einrichtung: Calibr at Scripps Research, La Jolla, California 92037, United States. Hauptthemen laut MEDLINE: Toxoplasma, Pyrrolidines, Brain, Phenylalanine-tRNA Ligase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Science and Engineering Research Board, Division of Microbiology and Infectious Diseases.
Abstract (Originalsprache)
Previous studies have shown that bicyclic azetidines are potent and selective inhibitors of apicomplexan phenylalanine tRNA synthetase (PheRS), leading to parasite growth inhibition in vitro and in vivo, including in models of Toxoplasma infection. Despite these useful properties, additional optimization is required for the development of efficacious treatments of toxoplasmosis from this inhibitor series, in particular, to achieve optimal exposure in the brain. Here, we describe a series of PheRS inhibitors built on a new bicyclic pyrrolidine core scaffold designed to retain the exit-vector geometry of the isomeric bicyclic azetidine core scaffold while offering avenues to sample diverse chemical space. Relative to the parent series, bicyclic pyrrolidines retain reasonable potency and target selectivity for parasite PheRS vs host. Further structure-activity relationship studies revealed that the introduction of aliphatic groups improved potency and ADME and PK properties, including brain exposure. The identification of this new scaffold provides potential opportunities to extend the analogue series to further improve selectivity and potency and ultimately deliver a novel, efficacious treatment of toxoplasmosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Calibr at Scripps Research, La Jolla, California 92037, United States.
- Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri 63130, United States.
- Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, Massachusetts 02142, United States.
- Molecular Medicine-Structural Parasitology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi 110067, India.
- ICMR-NIMR, Sector-8, Dwarka, New Delhi 110077, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
ORCID-Profile: Jochen Zoller, Amit Sharma, Stuart L Schreiber, Bruno Melillo, L David Sibley, Arnab K Chatterjee
Förderung
- NIAID NIH HHS
- Science and Engineering Research Board
- Division of Microbiology and Infectious Diseases
Zitieren
APA
Ence, C. C., Uddin, T., Borrel, J., Mittal, P., Xie, H., Zoller, J., Sharma, A., Comer, E., Schreiber, S. L., Melillo, B., Sibley, L. D., & Chatterjee, A. K. (2024). Bicyclic Pyrrolidine Inhibitors of Toxoplasma gondii Phenylalanine t-RNA Synthetase with Antiparasitic Potency In Vitro and Brain Exposure. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.4c00170
Vancouver
Ence CC, Uddin T, Borrel J, Mittal P, Xie H, Zoller J, et al. Bicyclic Pyrrolidine Inhibitors of Toxoplasma gondii Phenylalanine t-RNA Synthetase with Antiparasitic Potency In Vitro and Brain Exposure. ACS Infectious Diseases. 2024. doi:10.1021/acsinfecdis.4c00170
BibTeX
@article{Ence2024,
author = {Ence, Chloe C and Uddin, Taher and Borrel, Julien and Mittal, Payal and Xie, Han and Zoller, Jochen and Sharma, Amit and Comer, Eamon and Schreiber, Stuart L and Melillo, Bruno and Sibley, L David and Chatterjee, Arnab K},
title = {Bicyclic Pyrrolidine Inhibitors of Toxoplasma gondii Phenylalanine t-RNA Synthetase with Antiparasitic Potency In Vitro and Brain Exposure},
journal = {ACS Infectious Diseases},
year = {2024},
doi = {10.1021/acsinfecdis.4c00170}
}
EUVIMED